Takeda Chemical Industries, Inc.

Mitsubishi Denki Kabushiki Kaisha

Mitsubishi Electric Semiconductor Software Co., Ltd

Mitsubishi Electric System Lsi Design Corporation

Mitsubishi Electric Semiconductor Software Corporation

Yukio Fujisawa

Takashi Sohda

Junji Mizoguchi

Tsuneo Yasuma

Masayuki Takizawa

Masakuni Kori

Shuji Hinuma

Hiroyuki Watanabe

Tsunehiko Fukuda

Aki Mayumi

Hiroaki Konishi

Shun'ichi Kuroda

Yu Momose

Osamu Nishimura

Yuji Ishihara

Shigeyuki Takada

Zen-ichi Terashita

Yoshiaki Uda

Shigetoshi Tsubotani

Satoru Oi

Yasuaki Itoh

Toshihiko Kanzaki

Naoki Furuyama

Tatsuo Yamamoto

Shirasaki Mikio

Takizawa Masayuki

Aki Aono

Hans-Michael Loch

Christoph Gottschalk

Isao Takinoue

Kazutoshi Miyamoto

Haruo Suide

Thermogenic composition and benzazepine thermogenics

An address match determining device has an address filter memory (,) for storing a matrix or table having a plurality of elements each of which is a 1-bit address match determination data indicating whether or not a corresponding N-bit address code is available, and is distinguished by a pair of a first index composed of the m most significant or high-order m bits of the corresponding address code and a second index composed of the remaining lowest or low-order (N&minus;m) bits of the corresponding address code. A received-address latch (,) extracts the high-order m bits and remaining low-order (N&minus;m) bits from an address code latched thereinto. The device searches through the table for one 1-bit address match determination data specified by the first index composed of the extracted high-order m bits and the second index composed of the extracted low-order (N&minus;m) bits, and then determines whether or not the latched address is available on the basis of the 1-bit address match determination data searched for.

Address match determining device, communication control system, and address match determining method

Cysteine protease inhibitor

The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.

Method for treating osteoporosis

Disclosed are (1) a fused protein obtained by combining an antigen used for vaccine and a lymphokine by the application of gene engineering, (2) a recombinant DNA containing a nucleotide sequence coding for the above fused protein, (3) a transformant bearing the above recombinant DNA, (4) a method for producing the fused protein which comprises cultivating the above transformant, producing and accumulating the above fused protein in a culture, and collecting the fused protein, and (5) a hybrid protein obtained by chemically combining an antigen used for vaccine with a lymphokine. The resulting fused and hybrid proteins have strong immunogenicity.

DNA encoding a fusion protein comprising a viral antigen and lymphokine

The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof. Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.

Alcohol or aldehyde derivatives and their use

A switching regulator is composed of digital circuits only. A switching regulator (30) comprises a driver (2) for directly controlling the operation of a switching transistor (1), and an OR gate (6) for determining the logic issued by the driver (2). An output terminal (Q) of an RS flip-flop (5) is connected to one input end of the OR gate (6), the output of a timer (40c) is applied to a set terminal (S) of the RS flip-flop (5), and the output of a comparator (4) is applied to a reset terminal (R1) through an OR gate (7). At a non-reverse input end of the comparator (4), a reference voltage (VE) is applied by a D/A convertor (40b), while a feedback voltage (VFB) is applied to a reverse input end. Accordingly, chopping of the switching transistor (1) is done on the basis of a rectangular pulse.

All digital switching regulator for use in power supplies, battery

The present invention relates to (1) a human angiotensin II type 1 receptor protein, a recombinant DNA containing a gene which codes for said protein, a transformant carrying said DNA, production of said protein, and anti-angiotensin II substance screening methods using transformants containing said protein.

Angiotensin II type-1 receptor proteins and screening assays using such

A compound of the general formula: ##STR1## wherein R.sup.1 represents a carboxyl group which may optionally be esterified or amidated; R.sup.2 represents a cyclic group which may optionally be substituted or a polar group; n is an integer of 0 to 6; R.sup.3 represents hydrogen or a hydrocarbon residue which may optionally be substituted; R.sup.4 represents (1) a hydrocarbon residue which is substituted by an optionally protected amino group or (2) an alkenyl group; or R.sup.3 and R.sup.4 may be combined with the adjacent nitrogen atom to form a heterocyclic group containing at least two hetero atoms, or a salt thereof. The compound or a salt thereof of the present invention inhibits thiol proteases such as cathepsin L and B and serves well as a prophylactic/therapeutic agent for bone diseases such as osteoporosis.

Epoxysuccinic acid derivatives

Interleukin-2/viral antigen protein chimers

A pharmaceutical composition containing a physiologically active peptide or protein which is poorly absorbable through the gastrointestinal tract and heat-labile enterotoxin B subunit brings an increased absorbability of said peptide or protein into the mammalian body when administered through mucosa.

Pharmaceutical composition and its mucosal use

(1) a compound represented by the following formula (I): ##STR1## wherein R represents a hydrocarbon group or heterocyclic group which may be substituted; the ring A represents a pyridine ring having a substituent or a thiazole ring which may be substituted; or a pharmaceutically acceptable salt thereof, and a method of its production, and (2) an endothelin receptor antagonist, an cathepsin B inhibitor or a bone resorption suppressor having as an active ingredient a compound represented by the following formula (I'): ##STR2## wherein R has the same definition as in term (1); the ring A' represents a pyridine ring or thiazole ring which may be substituted; or a pharmaceutically acceptable salt thereof.

Condensed thiadiazole derivative, method of its production, and use

A unique word detecting apparatus comprising a preamble code detecting circuit 202 for detecting a preamble code PR to be transmitted before the unique word UW, a unique word detecting circuit 204 for holding in advance the data of the unique word UW to be detected, an error detecting circuit 203 for comparing the external data with the unique word UW successively bit by bit only when and after the preamble code PR is detected and for outputting an error signal E when not coincide, and a unique word detecting circuit 204 for counting the number of outputs of the error signal E and for outputting a detecting signal DT indicating that the unique word UW has been detected when the count value is equal to or smaller than a predetermined value. Only when the preamble code PR transmitted before the unique word UW is detected, the external data ED is compared with the unique word UW successively bit by bit, the number of uncoincident bits is counted, and when the count value is equal to or smaller than a predetermined value, the detecting signal DT indicating that the unique word UW has been detected is outputted.

Unique word detecting apparatus and unique word detecting method

Growing community of inventors

Kobe, Japan

Yukio Fujisawa